Overview

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

Status:
Active, not recruiting

Trial end date:
2021-01-01

Target enrollment:

Participant gender:

Summary

This is a multi-institutional, randomized, placebo controlled, double-blinded phase II trial of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer who have achieved at least stable disease on first-line chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Matthew Galsky

Collaborators:

Hoosier Cancer Research Network
Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab